InvestorsHub Logo
Followers 11
Posts 1565
Boards Moderated 0
Alias Born 09/19/2006

Re: None

Wednesday, 03/15/2017 12:19:25 PM

Wednesday, March 15, 2017 12:19:25 PM

Post# of 6377
Earnings conference results:

There are now 6 sites administering the BP1001 trial for AML. No trial in CML has started. The IND for BP1002 in Lymphoma has not occurred.

BPTH has opened a lab in Houston to develop new drugs.

9 million in the bank as of 12/31/16.

Maxim questions:

How many patients are enrolled in the AML study to date? No response to this question but the company expects to enroll 18 to 19 by the end of the year. The next study would require 196 new patients.

RR question:

The CML toxic portion of trial to open at MD Anderson in a few months.

For the time being the company will focus on completing the AML trial which will burn 8 million this year alone. More funds will be needed.

No reason given for the one day delay in the earnings report.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News